Reelin Protein: Could It Repair Leaky Gut & Ease Depression?

Could a single injection one day offer relief for both a “leaky gut” and the debilitating symptoms of depression? Emerging research suggests this may not be as far-fetched as it sounds. Scientists at the University of Victoria (UVic) have identified a protein, Reelin, that appears to play a crucial role in maintaining gut health and potentially alleviating depressive symptoms.

The Gut-Brain Connection and Chronic Stress

The gastrointestinal system, often referred to as the “gut,” is responsible for carefully regulating which nutrients enter the bloodstream. However, chronic stress, and conditions like major depressive disorder (MDD), can disrupt this delicate balance. Over time, this disruption can lead to increased permeability of the gut barrier – a condition commonly known as “leaky gut.”

When the gut barrier becomes more permeable, harmful bacteria and toxins can escape into circulation, triggering an immune response and inflammation. This inflammation, researchers are discovering, can worsen depressive symptoms. Strategies to strengthen the gut barrier may offer a novel approach to preventing or mitigating the severity of MDD.

Reelin: A Key Player in Gut and Brain Health

The research, published in the journal Chronic Stress, focuses on Reelin, a glycoprotein found throughout the body – in the brain, blood, liver, and intestines. According to Hector Caruncho, professor of medical sciences at UVic and the study’s corresponding author, therapies targeting Reelin may offer a new way to address both gut and brain health simultaneously.

“This study aimed to understand the role of Reelin in the gut, especially under conditions of chronic stress,” says Caruncho. “The gut-brain axis is becoming essential to understanding many psychiatric disorders, including depression.”

Restoring Reelin Levels in Preclinical Models

In preclinical studies, researchers observed that chronic stress led to a reduction in Reelin levels within the intestines. Remarkably, a single injection of just 3 micrograms (µg) of Reelin was sufficient to restore those levels to normal. This finding suggests a potential therapeutic pathway for addressing both gut dysfunction and its associated mental health consequences.

Evidence Linking Reelin to Depression and Gut Repair

Previous research has indicated that individuals diagnosed with major depressive disorder often exhibit lower levels of Reelin in their brains. Similar reductions in Reelin have been observed in rodents subjected to chronic stress. In these animal models, a single intravenous injection of 3 µg of Reelin demonstrated antidepressant-like effects.

prior work has established that Reelin is essential for the healthy renewal of the gut lining. The cells lining the gut are normally replaced every four to five days, a rapid turnover crucial for protecting against damage from potentially harmful substances.

Ciara Halvorson, a neuroscience PhD student at UVic and the study’s first author, explains the potential implications: “Taken together, these results may have important implications for the management of major depressive disorder, especially for people who live with both depression and gastrointestinal conditions.”

Protecting the Gut to Support Mental Wellbeing

The protective effect of Reelin may stem from its ability to support the renewal of the gut lining. By maintaining the integrity of this barrier, Reelin could potentially prevent the leakage of gut material that triggers inflammatory immune responses and, worsens depression symptoms.

“If Reelin protects against leaky gut by supporting the renewal of the gut lining, Reelin may thereby protect against the worsening of depression symptoms triggered by inflammatory immune responses to leaked gut material,” researchers noted.

Future Directions and Funding

While these findings are promising, further research is necessary before Reelin-based treatments can be implemented in clinical practice. However, the current evidence points towards a novel therapeutic approach that targets both the brain and the gut, potentially offering a more comprehensive strategy for treating depression.

This research was supported by funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC).